A case is described of a patient who developed local cutaneous hypersensitivity soon after commencing treatment with monocomponent insulins (MCI). This appears to be the first record of such a case.
Introduction
Monocomponent insulins (MCI) were developed by Schlichtkrull et al. (1972) 
Comment
The rapid onset of symptoms and signs suggested an immediate Type I hypersensitivity reaction. However, the skin tests were more in keeping with a Type III hypersensitivity resulting from the combination of antigen with circulating antibody. The fact that there occurred a reaction to both of the depot MCIs could be interpreted as indicating hypersensitivity to the carrier rather than to the insulin itself. However, the clinical findings were against this as she was observed repeatedly to react to both the soluble and depot MCIs. Although the claims that MCIs are virtually nonantigenic (Schlichtkrull et al., 1972; Czyzyk et al., 1974) have been challenged (Yue and Turtle, 1975) , it is generally considered that they may benefit patients with insulin hypersensitivity as well as those with lipodystrophy and insulin resistance. Several workers have expressed the view that with MCI cutaneous allergies are largely abolished and 'will probably no longer be observed' (Teuscher, 1975) .
Novo Industries in their promotional literature state that 'localized and generalized cutaneous allergies have not been reported with Novo MCI'. However, a generalized allergic reaction to MCI has recently been described in a patient who had repeatedly suffered local cutaneous hypersensitivity reactions to conventional insulins (Leslie, 1977 
